JP2021184731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021184731A5 JP2021184731A5 JP2021128846A JP2021128846A JP2021184731A5 JP 2021184731 A5 JP2021184731 A5 JP 2021184731A5 JP 2021128846 A JP2021128846 A JP 2021128846A JP 2021128846 A JP2021128846 A JP 2021128846A JP 2021184731 A5 JP2021184731 A5 JP 2021184731A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- antibody
- binding
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462010117P | 2014-06-10 | 2014-06-10 | |
| US62/010,117 | 2014-06-10 | ||
| EP15305078.6A EP2955196A1 (en) | 2014-06-10 | 2015-01-23 | Antibodies directed against CD127 |
| EP15305078.6 | 2015-01-23 | ||
| JP2017517406A JP7324565B2 (ja) | 2014-06-10 | 2015-06-10 | Ｃｄ１２７に対する抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517406A Division JP7324565B2 (ja) | 2014-06-10 | 2015-06-10 | Ｃｄ１２７に対する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021184731A JP2021184731A (ja) | 2021-12-09 |
| JP2021184731A5 true JP2021184731A5 (enExample) | 2022-03-03 |
Family
ID=52434718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517406A Active JP7324565B2 (ja) | 2014-06-10 | 2015-06-10 | Ｃｄ１２７に対する抗体 |
| JP2021128846A Pending JP2021184731A (ja) | 2014-06-10 | 2021-08-05 | Ｃｄ１２７に対する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517406A Active JP7324565B2 (ja) | 2014-06-10 | 2015-06-10 | Ｃｄ１２７に対する抗体 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10428152B2 (enExample) |
| EP (2) | EP2955196A1 (enExample) |
| JP (2) | JP7324565B2 (enExample) |
| KR (1) | KR102612930B1 (enExample) |
| CN (1) | CN106715471B (enExample) |
| AP (1) | AP2016009599A0 (enExample) |
| AU (1) | AU2015273532C1 (enExample) |
| BR (1) | BR112016028755B1 (enExample) |
| CA (1) | CA2950823A1 (enExample) |
| CL (1) | CL2016003172A1 (enExample) |
| CR (1) | CR20160576A (enExample) |
| EA (1) | EA039303B1 (enExample) |
| HK (1) | HK1231487A1 (enExample) |
| IL (1) | IL249449B (enExample) |
| MA (1) | MA40202A (enExample) |
| MX (1) | MX376066B (enExample) |
| MY (1) | MY190889A (enExample) |
| NZ (1) | NZ726932A (enExample) |
| PE (1) | PE20170324A1 (enExample) |
| PH (1) | PH12016502445A1 (enExample) |
| RU (1) | RU2734076C2 (enExample) |
| SA (1) | SA516380455B1 (enExample) |
| SG (1) | SG11201610036PA (enExample) |
| TN (1) | TN2016000528A1 (enExample) |
| UA (1) | UA125366C2 (enExample) |
| WO (1) | WO2015189302A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201404991YA (en) | 2012-02-23 | 2014-09-26 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| AU2016239949A1 (en) | 2015-03-31 | 2017-09-07 | Sorriso Pharmaceuticals, Inc. | Peptide construct having a protease-cleavable linker |
| KR102908806B1 (ko) | 2015-10-22 | 2026-01-07 | 주노 테라퓨틱스 게엠베하 | 세포의 배양 방법 및 이를 위한 키트와 장치 |
| EP3405491A1 (en) | 2016-01-21 | 2018-11-28 | VHsquared Limited | Polypeptides |
| MA43767B1 (fr) | 2016-02-29 | 2019-08-30 | Ose Immunotherapeutics | Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer |
| CN110392695B (zh) * | 2016-12-09 | 2021-02-02 | Ose免疫疗法 | 针对cd127的抗体和多肽 |
| US12258577B2 (en) | 2017-08-29 | 2025-03-25 | Ose Immunotherapeutics | Method effector cells using anti-CD127 antibodies for applications in cell therapy |
| CN110117325B (zh) * | 2018-03-09 | 2023-06-20 | 重庆市畜牧科学院 | 一种猪cd127多肽及其编码基因和应用 |
| CN118894938A (zh) | 2019-01-22 | 2024-11-05 | 百时美施贵宝公司 | 抗IL-7Rα亚基的抗体及其用途 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| JP7692844B2 (ja) * | 2019-06-21 | 2025-06-16 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| US12570736B2 (en) | 2019-06-21 | 2026-03-10 | Sorriso Pharmaceuticals, Inc. | Compositions |
| CA3144566A1 (en) | 2019-06-21 | 2020-12-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| AU2021262748A1 (en) | 2020-04-27 | 2022-12-01 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting CD127 and use thereof |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| JP2025518164A (ja) | 2022-05-30 | 2025-06-12 | オセ イムノセラピューティクス | Ｉｌ７ｒモジュレーター活性のバイオマーカー |
| CN115925955B (zh) * | 2022-12-30 | 2025-09-26 | 浙江正熙生物技术有限公司 | 一种抗cd127抗体及其制备方法和应用 |
| EP4646274A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| AU2024365145A1 (en) * | 2023-10-26 | 2026-05-07 | National Cancer Center | Antibody against interleukin-7 receptor (il-7r), and antibody-drug conjugate (adc) including said antibody |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN118638236B (zh) * | 2024-07-09 | 2025-03-14 | 武汉爱博泰克生物科技有限公司 | 抗人cd127蛋白的抗体、抗体偶联物及其应用 |
| WO2026022216A1 (en) | 2024-07-23 | 2026-01-29 | Ose Immunotherapeutics | Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases |
| WO2026033132A1 (en) | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| WO2026062296A1 (en) | 2024-09-23 | 2026-03-26 | Ose Immunotherapeutics | Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r |
| WO2026132078A1 (en) * | 2024-12-17 | 2026-06-25 | Ose Immunotherapeutics | Uses of anti-cd127 antibodies in the treatment of patients suffering from an inflammatory bowel disease and at high risk of relapse |
| WO2026159138A1 (en) * | 2025-01-21 | 2026-07-30 | Ose Immunotherapeutics | Therapy by antagonizing il-7 or cd127, and tl1a or tnfrsf25 |
| WO2026159136A1 (en) * | 2025-01-21 | 2026-07-30 | Ose Immunotherapeutics | Therapy by antagonizing il-7 or cd127, and tnf-alpha |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| ES2686593T3 (es) | 2006-05-31 | 2018-10-18 | The Regents Of The University Of California | Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+ |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| WO2010085643A1 (en) | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| CA2787070A1 (en) | 2010-01-28 | 2011-08-04 | Ian Kirby | Cd127 binding proteins |
| AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| MA43767B1 (fr) | 2016-02-29 | 2019-08-30 | Ose Immunotherapeutics | Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer |
-
2015
- 2015-01-23 EP EP15305078.6A patent/EP2955196A1/en not_active Withdrawn
- 2015-06-10 BR BR112016028755-0A patent/BR112016028755B1/pt active IP Right Grant
- 2015-06-10 CA CA2950823A patent/CA2950823A1/en active Pending
- 2015-06-10 SG SG11201610036PA patent/SG11201610036PA/en unknown
- 2015-06-10 MX MX2016016236A patent/MX376066B/es active IP Right Grant
- 2015-06-10 TN TN2016000528A patent/TN2016000528A1/en unknown
- 2015-06-10 AP AP2016009599A patent/AP2016009599A0/en unknown
- 2015-06-10 US US15/317,355 patent/US10428152B2/en active Active
- 2015-06-10 RU RU2016151265A patent/RU2734076C2/ru active
- 2015-06-10 PE PE2016002699A patent/PE20170324A1/es unknown
- 2015-06-10 MA MA040202A patent/MA40202A/fr unknown
- 2015-06-10 KR KR1020177000724A patent/KR102612930B1/ko active Active
- 2015-06-10 CN CN201580043066.1A patent/CN106715471B/zh active Active
- 2015-06-10 HK HK17104912.8A patent/HK1231487A1/zh unknown
- 2015-06-10 WO PCT/EP2015/062993 patent/WO2015189302A1/en not_active Ceased
- 2015-06-10 MY MYPI2016002094A patent/MY190889A/en unknown
- 2015-06-10 EA EA201692460A patent/EA039303B1/ru unknown
- 2015-06-10 AU AU2015273532A patent/AU2015273532C1/en active Active
- 2015-06-10 JP JP2017517406A patent/JP7324565B2/ja active Active
- 2015-06-10 EP EP15727989.4A patent/EP3155014A1/en active Pending
- 2015-06-10 NZ NZ726932A patent/NZ726932A/en unknown
- 2015-06-10 UA UAA201613258A patent/UA125366C2/uk unknown
- 2015-06-10 CR CR20160576A patent/CR20160576A/es unknown
-
2016
- 2016-12-06 PH PH12016502445A patent/PH12016502445A1/en unknown
- 2016-12-07 IL IL249449A patent/IL249449B/en active IP Right Grant
- 2016-12-08 SA SA516380455A patent/SA516380455B1/ar unknown
- 2016-12-09 CL CL2016003172A patent/CL2016003172A1/es unknown
-
2019
- 2019-08-05 US US16/532,000 patent/US11440964B2/en active Active
-
2021
- 2021-08-05 JP JP2021128846A patent/JP2021184731A/ja active Pending
-
2022
- 2022-09-09 US US17/941,885 patent/US12371502B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102821932B1 (ko) | 항-ccr8 항체 및 이의 용도 | |
| JP7325936B2 (ja) | 改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物 | |
| JP2017522903A5 (enExample) | ||
| JP7011574B2 (ja) | Ｆｌｔ３及びｃｄ３に対する抗体構築物 | |
| JP6879998B2 (ja) | Ｃｄ７０及びｃｄ３に対する抗体構築物 | |
| JP6726168B2 (ja) | Ｃｄｈ１９およびｃｄ３に対する抗体コンストラクト | |
| JP6907124B2 (ja) | Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物 | |
| JP7324565B2 (ja) | Ｃｄ１２７に対する抗体 | |
| KR20240118898A (ko) | Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물 | |
| SA515360253B1 (ar) | أجسام مضادة مُميزة لألفا سينوكلين | |
| TW201708261A (zh) | Ｄｌｌ３及ｃｄ３抗體構築體 | |
| JP2014518898A (ja) | Ｍｃａｍアンタゴニスト及び治療の方法 | |
| KR20160065981A (ko) | 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| TW201922773A (zh) | 雙特異性抗cd307e及抗bcma嵌合抗原受體之製造方法及用途 | |
| AU2014305658A1 (en) | An antibody therapy for amyloid beta disease | |
| CA2986210C (en) | Novel anti-human ngf antibody fab fragment | |
| KR20240006586A (ko) | Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도 | |
| US11702470B2 (en) | Use of CXCL13 binding molecules to promote peripheral nerve regeneration | |
| JP2024526154A (ja) | フィブロネクチン－インテグリン相互作用及びシグナル伝達を検出及び調節するための組成物及び方法 | |
| WO2025171411A1 (en) | Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions | |
| CN121930341A (zh) | Tl1a结合分子及其应用 | |
| KR20230144870A (ko) | Mincle 억제제를 포함하는 신경병성 통증 치료용 약학 조성물 | |
| WO2026056681A1 (zh) | 靶向人cd33的人源化抗体及其应用 | |
| CN111100211A (zh) | 一种Fc融合蛋白及其应用 | |
| EA046884B1 (ru) | Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение |